about
[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases.Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.PD6-3-3: Medical and economical impact of bone metastases in lung cancer patients: a prospective French national, multicentric study (GFPC 06-01 study)Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTEThe TAILOR study: to agree or to disagree?
P50
Q33164841-A861AD7F-3BD0-47DF-8F29-A19CFC03BCB8Q33591738-2F4B6697-7869-4C94-8469-2B5ABECA6255Q33804858-A1628651-0974-4CDE-B045-7B94AAD57EC5Q34914499-F3357973-A354-4A1D-9F43-401E9A94C93FQ38270016-2FEB8BA6-C7AF-4E96-B009-223E6AAF63D8Q38629823-CB9BC268-1F14-46AD-B748-A10478CB16D5Q39619779-C7D06793-261B-4EEE-A5B7-2F8E9B30D912Q40096915-B4BCDA61-A2C1-4E1C-8371-A97DCCE0FE10Q41683156-52085450-8E53-4182-9AC1-76B2B537C292Q42245908-DBA3C426-9E09-49F3-8508-F73D406ED2DAQ47096671-4FE5FD02-D0D7-49AA-B75C-3B35A5F7966EQ47604110-28A2305F-4FF7-4835-85EF-15F8AE79DDBCQ47822925-E4F65488-CBC9-4415-8D52-C48714AB6C19Q48606434-BF540B7E-9E73-44A8-B5D5-CC2E855714D7Q49953686-8EBE1856-475B-4CF8-A8BB-E6B7A5F5847BQ53807424-2558BE33-158C-40C3-B3E5-70A8F11D6E85Q54311958-1E435DC4-2F2F-4F0B-8ACB-34D9908A79B1Q60473150-4CD4BA60-0C81-4152-B499-6B235E0FC6B7Q87460294-B0E58D72-9B3E-4F76-84D5-2C515840D4B9Q87721153-38B91C0F-A078-4FF5-88B3-077723BED1CF
P50
name
Clarisse Audigier-Valette
@en
type
label
Clarisse Audigier-Valette
@en
prefLabel
Clarisse Audigier-Valette
@en